New Dual-Targeting CAR t therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT04697940
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 17 times
Summary
This study tests a new treatment for people with B-cell Non-Hodgkin's lymphoma that has come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells that are modified to target two proteins (CD19 and CD20) on cancer cells, plus a drug called decitabine to make the cells work better. The goal is to see if this approach is safe and effective, with up to 33 participants in two phases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biotherapeutic Department of Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.